Physician profile
Stephen Grado
NPI 1083230916
$3,011.63
in general payments reported to CMS, 2019-2025
28 companies · $969 in 2025
The $969 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,033 · 2024: $1,010 · 2025: $969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,652 · Education: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,651.53 |
| Education | $360.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $379.00 | 2023-2025 | Ensite, Merlin@Home |
| Abiomed | $224.03 | 2023-2024 | Impella |
| Regeneron Healthcare Solutions, INC. | $209.25 | 2025 | Evkeeza |
| Astrazeneca Pharmaceuticals Lp | $189.74 | 2024-2025 | Wainua, Farxiga |
| Novo Nordisk INC | $169.90 | 2024-2025 | Wegovy |
| Pfizer INC. | $169.48 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $157.73 | 2023-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $153.74 | 2023-2025 | |
| Acist Medical Systems, INC. | $149.45 | 2023 | |
| Cvrx, INC. | $145.58 | 2024 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.91 | 2023-2025 | Jardiance |
| Boston Scientific Corporation | $123.30 | 2023-2025 | Latitude Communicator Power Supply |
| Scpharmaceuticals INC. | $122.82 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $91.29 | 2025 | Verquvo, Winrevair |
| Amgen INC. | $90.53 | 2023 | Repatha |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $87.39 | 2024-2025 | Inspire |
| Alnylam Pharmaceuticals INC. | $77.21 | 2025 | Amvuttra |
| United Therapeutics Corporation | $64.95 | 2024-2025 | Tyvaso, Tyvaso |
| Bridgebio Pharma, INC. | $61.31 | 2025 | Attruby |
| Medtronic, INC. | $31.61 | 2023-2025 | Cobalt Dr Mri Surescan |
| Janssen Pharmaceuticals, INC | $31.49 | 2024 | Xarelto |
| Chiesi USA, INC. | $30.02 | 2023-2024 | Cleviprex, Kengreal, Juxtapid |
| Cordis US Corp. | $24.70 | 2025 | Mynx Control |
| Procyrion, INC. | $23.60 | 2025 | Aortix System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.67 | 2023 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $19.62 | 2023 | |
| Irhythm Technologies, INC. | $16.96 | 2024 | Zio Monitor, Zio Xt Patch |
| Biotronik INC. | $13.35 | 2023 | Renamic Neo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Grado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.